Authors: Jade Parker, Editor
Previous research has demonstrated a daily treatment for 2 months of conventionally fractionated high dose external beam radiation therapy (CRT), decreases prostate cancer recurrence and improves metastasis-free survival. Additional studies have demonstrated that moderate hypo-fractionated radiation therapy (HRT), consisting of daily treatment for 1 month using a larger dose per treatment, provides a similar low risk of recurrence and may even be lower with HRT than CRT.
In this study, the researchers wanted to test the latter hypothesis. To achieve this, the team led by investigators at Brigham and Women’s Hospital (MA, USA) analyzed data from over 5000 men from three randomized studies comparing HRT with CRT in men with prostate cancer. The findings were recently published in European Urology Focus.